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•	 Factor VII has important role in the treatment of coagulation and hemophilic  disease.
•	 Recombinant FVII was expressed in Iranian Lizard Leishmania.
•	 The amidolytic activity of rhFVII was about 0.0125 IU/ml in cell pellet.
•	 No amildolytic activity was observed in the supernatant.
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ABSTRACT
Over many years, variable gene expression systems have been used obtaining of Factor 
VII  protein, but each one has certain limitations. Therefore, the main goal of this study 
was to  assess the biological activity of purified and recombinant factor VII expressed 
in Iranian lizard Leishmania.  After transferring recombinant construct containing FVII 
gene to Leishmania, first, the expression of 55 kDa FVII protein in  transfected cells was 
confirmed by analyzing cell lysate using SDS-PAGE and Western Blotting techniques. 
Then,  FVII was purified by NI-NTA-His Tag- resin through an affinity chromatography. 
The chromogenic activity of human recombinant  Factor VII (amidolytic activity) in 
supernatant and pellet fractions of Leishmania  promastigotes was done using ELISA 
method. The amidolytic activity of rhFVII was about 0.0125 IU/ml in the concentrated 
cell sediment and 0  IU/ml in the supernatant in the first 60 minutes and after that time, 
none of the samples showed  acceptable activity.
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Introduction 
Factor VII is a plasma glycoprotein that plays an important 
role in the production of blood clotting fibrin  (Davie et 
al., 1979). Factor VII in active form and the presence of 
calcium and TF, activates factor X and IX (Persson et 
al., 1997; Hoffman et al., 1998).  Conversion of factor 
VII was activated by digestion between amino acid 
arginine 152 and  isoleucine 153 (Chao-Hung et al., 2006). 
Factor VII, due to its important role in the treatment of 
coagulation and hemophilic  disease, is of considerable 
interest (Hedner and Kisiel, 1983). So far, FVII gene 
was expressed in eukaryotic cells like  BHK, insects and 
mammalian cells (Hagen et al., 1988; Masroori et al., 
2010). The Leishmania tarantulae expression system 
has been considered according to  following advantages; 
a) easy to work with organisms like yeast and E. coli, b)
have the same  folding as protein synthesis by eukaryotic
systems, c) post-translational modifications similar to
 changes that occur in the mammalian cells, d) cells
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of enzyme. PNA changes in 405 nm  shows enzymatic 
activity, directly. 
Human plasma as a positive control and PBS as a 
negative control were considered. 100 μl of standards 
were added into the separated wells. Then, 100 μl of 
 concentrated culture supernatant, concentrated cell 
sediments, and cell sediment were added to  the other 
separated wells and incubated for 2 h at room temperature. 
Then, the microplate was washed with  Wash Buffer for 5 
times. 80 μl of Assay Mix was added to each well and 
incubated for 30  minutes at 37°C and after that, 20 μl of 
FXa substrate was added to each well and the  absorbance 
was read immediately at 405 nm. It was also studied after 
incubated at 37°C again for,  10 seconds, 25, 60 minutes.
 Results and Discussion
 Accuracy of recombinant pLEXSY-hyg2-FVII
To confirm the accuracy of the recombinant plasmid 
containing factor VII gene, PCR reaction was 
done using these primers: forward primer  (F3001): 
5’-GATCTGGTTGATTCTGCCAGTAG-3’ and reverse 
primer (B2): 5’- AGATGGTGTTGATCAGGGTCC-3’ 
and  980 bp PCR product of FVII gene and Leishmania 
rDNA gene was confirmed by agarose gel electrophoresis 
(Fig. 1).
proliferation in cultured media are cheap, e) in  contrast to 
the mammalian cell, the cell has a higher specific growth 
rate (Fritsche et al., 2007; Fritsche et al., 2008). These 
benefits  led to the production of recombinant FVII in 
Iranian Lizard Leishmania (Mirzaahmadi et al., 2011). In 
this study, a similar production system was run and the 
chromogenic  activity of human factor VII produced in 
Leishmania tarantulae was examined.
Materials and Methods
Production of protein (rFVII)
Human factor VII recombinant Plasmid pLEXY-hyg2 
was gifted from Mirzaahmadi (Mirzaahmadi et al., 
2011).  Recombinant plasmid pLEXsY-hyg2 was digested 
by SwaI enzyme (Bioneer Germany).  the transfection 
into the promastigotes of Iranian Lizard Leishmania 
was performed by electroporation (Eppendorf’s GEN 
PLUSES) (Robinson and Beverley, 2003). Transfected 
promastigotes were cultured in RPMI1640 and BHI 
medium  supplemented with FBS 10%, 100 mg/ml 
streptomycin (GIBCO, Pen-strep 15140) at 37°C. 
 Transfected Leishmania was confirmed by PCR 
reaction using the primers: forward primer  (F3001): 
5’-GATCTGGTTGATTCTGCCAGTAG-3’ (rDNA 
of Leishmania genome)  and reverse primer (B2): 
5’- AGATGGTGTTGATCAGGGTCC-3’ (from 764 t0 
784 bp of FVII gene). Expressed rhFVII in Iranian Lizard 
Leishmania was  electrophoresed on SDS-PAGE and 
stained by coomassie brilliant blue R250. Gel transferred 
onto  nitrocellulose membrane and FVII was confirmed by 
western blot analysis using a polyclonal antibody  against 
FVII. 
Protein (rFVII) purification
Transgenic Leishmania promastigotes were cultured 
in 10  ml of RPMI1640 and centrifuged at 500 rpm for 
5 minutes and the supernatant was separated from  cell 
pellet. Precipitate dissolved in lysis buffer containing 
1mM PMSF. The Suspension was  obtained by sonication 
(3 times with 20 seconds bursts), then, recombinant factor 
VII was  purified by affinity chromatography using Ni-
NTA His Tag Resin (Novagen). 
The chromogenic activity of rFVII
Recombinant FVII activity was assayed by human FVII 
 chromogenic activity assay kit (based on the indirect 
amidolytic activity). The specific  hrFVII polyclonal 
antibody that was coated at the bottom of a microplate, 
connect to FVII. In this  experiment, the amount of 
lipoprotein TF/FVIIa activating the FX was measured 
using an active  substrate, which could produce a yellow 
color (from Para Nitro Alanine (PNA)) in the presence 
Figure 1. Agarose gel electrophoresis of pLEXSY-hyg2-FVII: lane 
1: 980 bp as PCR product. Lane  2: the 100 bp DNA ladder marker .
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Expression of rhFVII by Iranian lizard Leishmania
Because N-glycosylation pattern and post-translational 
modification of Leishmania are similar to mammals 
(Niimi, 2012; Khan et al., 2017), we use this system for 
FVII expression.
Expression of rhFVII by Leishmania  was confirmed by 
SDS-PAGE and western blot. Leishmania promastigote 
was lysed and loaded  on 10% SDS-PAGE.  The gel was 
transferred onto the nitrocellulose membrane and rhFVII 
was  detected by polyclonal antibody against factor VII 
(Fig. 2). 
Verification of the purified product was also 
performed. Leishmania lysate passed through a column 
 chromatography of Ni-NTA-His Tag resin. The resin was 
loaded on the SDS-PAGE gel and after the electrophoresis, 
the gel was  transferred to the nitrocellulose membrane for 
western blot analysis using a polyclonal antibody  against 
FVII (Fig.3).
Measurement of rhFVII activity by chromogenic activity
Factor VII Human Chromogenic Activity Assay Kit 
(ab108830) has been developed to determine human FVII 
activity in plasma, serum and cell culture supernatants. 
The assay couples immuno-functional and indirect 
amidolytic assay (Abcam catalog for Factor VII Human 
Chromogenic Activity Assay Kit, ab108830). Osterud 
in 1983 was studied how to measure FVII and FVIIa 
activities by using  a direct method for FVIIa activity 
measurement. For FVII coagulant activity (FVIIc) 
coincides three methods considering,  1) quantification 
of the FVII antigen (FVII Ag), 2) assaying amidolytic 
activity (FVII am), 3) coagulation tests using  bovine 
tissue thromboplastin (VII bt) (Østerud, 1983).
In the present study, the rhFVII was expressed 
in Iranian Lizard Leishmania and was auto activated 
during purification (Pedersen et al., 1989).  FVII 
amidolytic activity was  measured by kit (ab108830). 
Figure 2. Western blot analysis. Lane 1 and 4: produced rhFVII protein, lane 2: empty. Lane 3:  protein weight marker.  
 





























Figure 3. Western blot analysis of purified protein; Lane 1: western blot of purified rhFVII. Lane 2: proteins size marker.
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The chromogenic activity of rhFVII was 0.0125 IU/
ml in  concentrated cell sediment and 0 IU/ml in the 
concentrated supernatant in the first 60 minutes and  after 
60 minutes any of the samples had not acceptable activity 
(Fig. 4). Based on the kit manual (ab108830), the standard 
dilutions (1/8), (1/16),  (1/32) (1/64), (1/128), (1/256) of 
stock solution shows the 0.2, 0.1, 0.05, 0.025, 0.0125, 
0.000  IU/ml activity of FVII. 
Conclusion
Upon vascular injury and tissue damage, the tissue 
factor (TF) and cell surface receptor binds together and 
activates FVII to FVIIa. The TF/FVIIa complex catalyzes 
the conversion of both factors IX to factor IXa and factor 
X to factor Xa to initiate coagulation via the extrinsic 
pathway (Seligsohn et al., 1978; van Dieijen-Visser et 
al., 1982). Very low levels of FVII are associated with 
severe coagulation disorders and elevation of factor VII 
in middle-aged subjected to an independent risk factor for 
subsequent ischemic heart disease (Hoffman et al., 1989; 
Suzuki et al., 1991).
Basile et al. proposed the production of recombinant 
 proteins in Leishmania tarantulae in 2009.  The 
Leishmania can successfully produce glycoproteins  with 
10% fructose and galactose as oligosaccharides, which 
are similar to mammals. The  Leishmania tarantulae 
expression system was proposed as a eukaryotic 
expression for  heterologous proteins (Basile and Peticca, 
2009).  Sodoyer in 2004 used BHK, HEK293, and CHO 
for expression of  rhFVII. The rhFVII was also expressed 
in insect cells, SF9 (Spodoptera Frugipedra) and also, 
 Baculovirus. Mammalian cell expression systems 
has several limitations, such as high-cost medium, the 
possibility  of contamination with viruses or prions, and 
the high cost of purification. In insect cells as a  model, 
the addition of complexes oligosaccharides in post-
translational modifications are defective, in  comparison 
with mammalian cells, and as a result, recombinant 
protein may exhibited altered  bioactivity (Sodoyer, 2004). 
Fritsche et al. in 2007 were studied characterizations 
of Leishmania tarentolae as an expression  system for 
recombinant protein expression (Fritsche and Sitz, 2007). 
Coagulation FVIIa expressed in Leishmania  Tarentolae, 
due to many advantages of this expression system, such as 
easy to work with this organism like E. coli and  yeast, same 
folding and post-translational modifications of proteins, 
similar to eukaryotic  systems, especially mammalian 
cells, reproducibility of Iranian lizard Leishmania cells 
(Kazemi et al., 2004), low cost culture media with high 
specific growth rate (Fritsche et al., 2008) than any 
other expression systems such  as BHK, HEK293, CHO, 
SF9 (Spodoptera frugiopedra) and mammalian cell 
expression  system (Berkner et al., 1988; Halabian et al., 
2009) and the activity of expressed FVII was examined. 
Mirzaahmadi et al. were also expressed rhFVII in Iranian 
 Lizard Leishmania expression system and could reduce 
clotting time of the sample to 30  seconds (Mirzaahmadi 
et al., 2011). In this study, rhFVII was successfully 
expressed by Iranian Lizard Leishmania, in the cell pellet, 
and exhibited acceptable amidolytic  activity. Therefore, 
Iranian lizard Leishmania can be a suitable expression 
system for production of active rFVII. 
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